MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 253 filers reported holding MYRIAD GENETICS INC in Q4 2017. The put-call ratio across all filers is 0.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $8,160,000 | -46.1% | 285,000 | -47.7% | 0.03% | -44.3% |
| Q2 2019 | $15,140,000 | -10.5% | 545,000 | +7.0% | 0.06% | -15.3% |
| Q1 2019 | $16,918,000 | +58.3% | 509,564 | +38.6% | 0.07% | +33.3% |
| Q4 2018 | $10,685,000 | -10.7% | 367,564 | +41.4% | 0.05% | +8.0% |
| Q3 2018 | $11,960,000 | +23.1% | 260,000 | 0.0% | 0.05% | +19.0% |
| Q2 2018 | $9,716,000 | +37.0% | 260,000 | +8.3% | 0.04% | +27.3% |
| Q1 2018 | $7,092,000 | +11.6% | 240,000 | +29.7% | 0.03% | +13.8% |
| Q4 2017 | $6,354,000 | -18.5% | 185,000 | -14.2% | 0.03% | -21.6% |
| Q3 2017 | $7,797,000 | +40.0% | 215,500 | 0.0% | 0.04% | +32.1% |
| Q2 2017 | $5,569,000 | +112.5% | 215,500 | +57.9% | 0.03% | +100.0% |
| Q1 2017 | $2,621,000 | +96.5% | 136,500 | +70.6% | 0.01% | +75.0% |
| Q4 2016 | $1,334,000 | +62.1% | 80,000 | +100.0% | 0.01% | +100.0% |
| Q3 2016 | $823,000 | – | 40,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |